[Critical role for p27 in mediating the antitumoral activity of a proteasome inhibitor].
Murielle P
MP
Serres
Arnaud
A
Besson
D000970:Antineoplastic Agents / Q000627:therapeutic use; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000502:physiology*; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D010456:Peptides, Cyclic / Q000627:therapeutic use; D061988:Proteasome Inhibitors
D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; D061988:Proteasome Inhibitors; C530877:argyrin A; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018844:Cyclin-Dependent Kinases